ReviewEpilepsia2024
Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper.
Review in Epilepsia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis.Epilepsia open · 2024Pooled it
- Lamotrigine add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2023Pooled it
- ABCB1 Expression in Pediatric Drug-Resistant Epilepsy: Insights from Paired Brain Tissue and Peripheral Blood Analysis.Indian journal of pediatrics · 2026Article
- Anti-Inflammatory and Antioxidant Strategies in Epilepsy: From Molecular Mechanisms to Threshold Management.International journal of molecular sciences · 2026Review
- Epilepsy and amygdalar enlargement: cause or consequence?Arquivos de neuro-psiquiatria · 2026Review
- Article
- A prospective observational study evaluating drug-related problems and their impact on patient-related outcomes in hospitalized epileptic patients.Scientific reports · 2026Observational
- Ibogalogs induce antiseizure activity in rodents by a mechanism involving 5-HTBiochemical pharmacology · 2026Article
- European Reference Networks - a flagship activity of the EU in the field of rare and complex diseases: from 2017 to 2025.Orphanet journal of rare diseases · 2026Review
- Characteristics of and risk factors for epilepsy after autoimmune and infectious encephalitis.BMC neurology · 2026Article
- A structured narrative review on VNS-treated drug-resistant epilepsy: EEG markers, neurochemical mechanisms, and future biomarker-driven computational directions.Frontiers in neuroscience · 2026Review
- Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force.Epilepsia · 2025Article
- Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders.Pharmacological reports : PR · 2025Review
- Movement Termination of Slow-Wave Sleep-A Potential Biomarker?Brain sciences · 2024Article
- Initial clinical evidence on biperiden as antiepileptogenic after traumatic brain injury-a randomized clinical trial.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
A variety of terms, such as "antiepileptic," "anticonvulsant," and "antiseizure" have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English-language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named "antiseizure medications". This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term "antiseizure" to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having "antiepileptogenic" or "disease-modifying" effects. A more-refined terminology to describe precisely these actions needs to be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.